Updated recommendations of the International dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America

Vista sencilla de Ć­tem
dc.contributor.authorTorres, Jaime
dc.contributor.authorFalleiros-Arlant, Luiza Helena
dc.contributor.authorGessner, Bradford D.
dc.contributor.authorDelrieu, Isabelle
dc.contributor.authorAvila-Aguero, Maria L.
dc.contributor.authorGiambernardino, H. I.G.
dc.contributor.authorMascareƱas, Abiel
dc.contributor.authorBrea, J.
dc.contributor.authorTorres, C. N
dc.contributor.authorCastellanos-Martinez, J. M.
dc.date.accessioned2020-05-11T19:32:14Z
dc.date.available2020-05-11T19:32:14Z
dc.date.issued2019
dc.description.abstractenglishDengue disease represents a large and growing global threat to public health, causing a significant burden to health systems of endemic countries. For countries considering vaccination as part of their Integrated Management Strategy for Prevention and Control of Dengue, the World Health Organization currently recommends the first licensed dengue vaccine, CYD-TDV for: individuals aged 9ā€Æyears or above from populations with high transmission rates, based on either seroprevalence criteria or pre-vaccination screening strategies, and for persons with confirmed prior exposure to infection in moderate to lower transmission settings. This paper describes the main conclusions of the Sixth Meeting of the International Dengue Initiative (IDI) held in June 2018, following release of a new product label by the manufacturer, updated WHO-SAGE recommendations, additional scientific evidence on vaccine performance, and reports of experiences by implementing countries. Considerations were made regarding the need for improving the quality of epidemiological and surveillance data in the region to help define the convenience of either of the two vaccination strategies recommended by WHO-SAGE. Extensive discussion was dedicated to the pros and cons of implementing either of such strategies in Latin America. Although, in general, a seroprevalence-based approach was preferred in high transmission settings, when cost-effectivity is favorable pre-vaccination screening is a convenient alternative. Cost-effectiveness evaluations can assist with the decisions by public health authorities of whether to introduce a vaccine. Where implemented, vaccine introduction should be part of a public health strategy that includes the participation of multiple sectors of society, incorporating input from scientific societies, ministries of heath, and civil society, while ensuring a robust communication program.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2019.09.010
dc.identifier.issn1873-2518
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2566
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalVaccinespa
dc.relation.ispartofseriesVaccine, 1873-2518, Vol. 37, Nro, 8, 2019, p. 6291-6298spa
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S0264410X19311983?via%3Dihub
dc.rights.creativecommons2019
dc.rights.localAcceso cerradospa
dc.subject.decsSalud pĆŗblicaspa
dc.subject.decsControl de enfermedades transmisiblesspa
dc.subject.decsEstudios seroepidemiolĆ³gicosspa
dc.subject.keywordsDengue vaccinespa
dc.subject.keywordsLatin Americaspa
dc.subject.keywordsUpdated recommendationsspa
dc.titleUpdated recommendations of the International dengue Initiative expert group for CYD-TDV vaccine implementation in Latin Americaspa
dc.title.translatedUpdated recommendations of the International dengue Initiative expert group for CYD-TDV vaccine implementation in Latin Americaspa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartĆ­culospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Torres, Jaime, Falleiros-Arlant, Luiza Helena, Gessner, Bradford D., Delrieu, Isabelle. Et.al_2019.pdf
TamaƱo:
318.44 KB
Formato:
Adobe Portable Document Format
DescripciĆ³n:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
TamaƱo:
1.71 KB
Formato:
Item-specific license agreed upon to submission
DescripciĆ³n:
Descargar

Colecciones

ArtĆ­culos